Hematological Malignancies Biotherapeutics Market

Global Hematological Malignancies Biotherapeutics Market Size, Trends & Analysis - Forecasts to 2027 By Condition (Leukemia, Lymphoma, and Myeloma), By Therapy Type (Biologics & Biosimilars, T-cell Therapies, and Stem Cell Therapies), By End-User (Hospitals, Cancer Centers, and Research and Academic Institutes), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa), Competitive Landscape Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on July 20 2024 with the latest and most recent market numbers

Hematological Malignancies Biotherapeutics Market Size

The Global Hematological Malignancies Biotherapeutics Market is projected to grow at a CAGR value of 10.8% from 2022 to 2027.

Hematological malignancies are a type of cancer that predominantly begin in the bone marrow or within the cells of the immune system. The growing investment in cancer therapeutics and the growing awareness surrounding cancer research have contributed to the growth of the hematological malignancies biotherapeutics market.

The growing prevalence of blood cancer and an increased emphasis on discovering innovative treatments are the primary factors contributing to the market's growth.

According to Globocan 2020, Asia had the greatest estimated incidence of leukemia, with 230,650 cases diagnosed in 2020, followed by Europe with 100,020 cases and North America with 67,784 cases. The Leukemia & Lymphoma Society estimates that 186,400 people in the U.S. will be diagnosed with leukemia, lymphoma, or myeloma in 2021. Leukemia, lymphoma, and myeloma will account for 9.8% of the estimated total number of new cancers cases diagnosed in the United States in 2021.

The growing adoption of stem cell therapies for treating lymphoma, amyloidosis, and myeloma, among other diseases, is expected to increase the demand for hematological malignancies biotherapeutics further.

Among the multiple types of cancer afflicting the human society, blood cancer is the fifth most common type of cancer. Blood cancer is also the leading cause of cancer-related deaths after lung cancer. The WHO estimates that over 300,000 people will die due to complications arising from leukemia in 2020. The growing number of patients suffering from blood cancers like leukemia, lymphoma, and Waldenstrom's macroglobulinemia will increase the demand for hematological malignancies biotherapeutics.

The growing number of collaborations between pharmaceutical companies and research institutions in cancer research is expected to influence the hematological malignancies therapeutics market positively. The growing incidence of cancer in countries with aging populations has increased investment in cancer research and treatment centers.

Stringent government regulations on drug development restrain the market. Pharmaceutical companies are expected to undergo multiple rounds of drug safety testing and should have the results and methodologies verified and approved by government agencies. These procedures are time-consuming and significantly increase the cost of development, resulting in higher prices for hematological malignancy therapeutics.

The market's growth is expected to be further restrained by the high cost of such therapeutics and the lack of sufficient insurance coverage in many countries.

Many optional treatment procedures without time constraints were postponed in the wake of the pandemic. The hematological malignancies therapeutics market was hampered as hospitals became hotspots for virus transmission due to a higher risk of infection among patients suffering from pre-existing medical conditions. However, delayed treatment is not suggested for serious diseases, particularly acute leukemia. As a result, essential rules and safeguards have recently been put in place to enable the treatment of hematologic malignancies during the pandemic while taking all precautions.

The hematological malignancies biotherapeutics market is driven mainly by the growing incidence of blood cancer, increasing investment in cancer research, growing cancer awareness initiatives, and the growing number of specialized cancer treatment facilities.

global hematological malignancies biotherapeutics market

Hematological Malignancies Biotherapeutics Market: By Condition

Based on the condition, the hematological malignancies biotherapeutics market is segmented into leukemia, lymphoma, and myeloma.

The leukemia segment is expected to hold the most significant piece of the market during the forecast period. The leukemia segment has been primarily driven by the growing number of people who have leukemia. Increasing investment in leukemia treatment and biologics has led to the domination of the leukemia segment.

Hematological Malignancies Biotherapeutics Market: By Therapy Type

Based on the various therapy types in the hematological malignancies biotherapeutics market, the market is segmented into biologics & biosimilars, T-cell therapies, and stem cell therapies. The biologics & biosimilars segment held the lion's share of the market. The growing number of pharmaceuticals available in the market and the growing investment in pharmaceutical research have been major drivers of this segment. The stem cell therapy segment is expected to become the fastest-growing segment owing to growing investment in stem cell research.

Hematological Malignancies Biotherapeutics Market: By End-User

Based on the various end-users, the market is segmented into hospitals, cancer centers, and research and academic institutes. The hospitals segment held the lion's share of the market. Most hospitals are often equipped to deal with cancer treatment and have oncologists on call. Many major hospitals have dedicated cancer treatment facilities headed by a team of world-class oncologists.

The cancer centers segment is also expected to become the fastest-growing segment during the forecast period. Increasing investment in cancer center facilities from private players and government institutions is the major driver of the segment.

asia pacific hematological malignancies biotherapeutics market

Hematological Malignancies Biotherapeutics Market: By Region

Based on region, the market can be segmented into various regions such as North America, Europe, Central and South America, the Middle East and North Africa, and Asia Pacific regions.

The North American region is expected to be the dominant force in the market during the forecast period. The growing geriatric population in the region has been one of the major contributors to the growth of the market in the region. The Leukemia & Lymphoma Society estimates that 186,400 people in the US will be diagnosed with leukemia, lymphoma, or myeloma in 2021. Leukemia, lymphoma, and myeloma will account for 9.8% of the estimated total number of new cancer cases diagnosed in the United States in 2021.

The APAC region is expected to become the fastest-growing segment during the forecast period. Growing investment in cancer research and cancer treatment facilities combined with an increased incidence of blood cancer among the population is expected to contribute to the growth of the market in the region.

Hematological Malignancies Biotherapeutics Market Share and Competitor Analysis

Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, bluebird bio, Inc., Amgen, AstraZeneca, F. Hoffmann-La Roche AG, Merck KGaA, Pfizer Inc., and Eli Lilly and Company, among others, are the key players in the hematological malignancies biotherapeutics market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Hematological Malignancies Biotherapeutics Industry Overview, 2020-2026

2.1.1 Industry Overview

2.1.2 Condition Overview

2.1.3 Therapy Type Overview

2.1.4 End-User Overview

2.1.6 Regional Overview

Chapter 3 Hematological Malignancies Biotherapeutics Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2020-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Rising prevalence of blood cancer

3.3.2 Industry Challenges

3.3.2.1 High cost of development and stringent regulations

3.4 Prospective Growth Scenario

3.4.1 Condition Growth Scenario

3.4.2 Therapy Type Growth Scenario

3.4.3 End-User Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 End-User Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Hematological Malignancies Biotherapeutics Market, By Condition

4.1 Condition Outlook

4.2 Leukemia

4.2.1 Market Size, By Region, 2020-2026 (USD Million)

4.3 Lymphoma

4.3.1 Market Size, By Region, 2020-2026 (USD Million)

4.4 Myeloma

4.4.1 Market Size, By Region, 2020-2026 (USD Million)

Chapter 5 Hematological Malignancies Biotherapeutics Market, By Therapy Type

5.1 Therapy Type Outlook

5.2 Biologics & Biosimilars

5.2.1 Market Size, By Region, 2020-2026 (USD Million)

5.3 T-cell Therapies

5.3.1 Market Size, By Region, 2020-2026 (USD Million)

5.4 Stem Cell Therapies

5.4.1 Market Size, By Region, 2020-2026 (USD Million)

Chapter 6 Hematological Malignancies Biotherapeutics Market, By End-User

6.1 Hospitals

6.1.1 Market Size, By Region, 2020-2026 (USD Million)

6.2 Cancer Centers

6.2.1 Market Size, By Region, 2020-2026 (USD Million)

6.3 Research and Academic Institutes

6.3.1 Market Size, By Region, 2020-2026 (USD Million)

Chapter 7 Hematological Malignancies Biotherapeutics Market, By Region

7.1 Regional outlook

7.2 North America

7.2.1 Market Size, By Country 2020-2026 (USD Million)

7.2.2 Market Size, By Condition, 2020-2026 (USD Million)

7.2.3 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.2.4 Market Size, By End-User, 2020-2026 (USD Million)

7.2.6 U.S.

7.2.6.1 Market Size, By Condition, 2020-2026 (USD Million)

7.2.4.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.2.4.3 Market Size, By End-User, 2020-2026 (USD Million)

7.2.7 Canada

7.2.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.2.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.2.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3 Europe

7.3.1 Market Size, By Country 2020-2026 (USD Million)

7.3.2 Market Size, By Condition, 2020-2026 (USD Million)

7.3.3 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.4 Market Size, By End-User, 2020-2026 (USD Million)

7.3.6 Germany

7.3.6.1 Market Size, By Condition, 2020-2026 (USD Million)

7.3.6.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.7 UK

7.3.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.3.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.8 France

7.3.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.3.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.9 Italy

7.3.9.1 Market Size, By Condition, 2020-2026 (USD Million)

7.3.9.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.9.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.10 Spain

7.3.10.1 Market Size, By Condition, 2020-2026 (USD Million)

7.3.10.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.10.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.11 Russia

7.3.11.1 Market Size, By Condition, 2020-2026 (USD Million)

7.3.11.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.3.11.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4 Asia Pacific

7.4.1 Market Size, By Country 2020-2026 (USD Million)

7.4.2 Market Size, By Condition, 2020-2026 (USD Million)

7.4.3 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.4.4 Market Size, By End-User, 2020-2026 (USD Million)

7.4.6 China

7.4.6.1 Market Size, By Condition, 2020-2026 (USD Million)

7.4.6.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.4.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.7 India

7.4.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.4.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.4.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.8 Japan

7.4.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.4.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.4.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.9 Australia

7.4.9.1 Market Size, By Condition, 2020-2026 (USD Million)

7.4.9.2 Market size, By Therapy Type, 2020-2026 (USD Million)

7.4.9.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.10 South Korea

7.4.10.1 Market Size, By Condition, 2020-2026 (USD Million)

7.4.10.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.4.10.3 Market Size, By End-User, 2020-2026 (USD Million)

7.5 Latin America

7.5.1 Market Size, By Country 2020-2026 (USD Million)

7.5.2 Market Size, By Condition, 2020-2026 (USD Million)

7.5.3 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.5.4 Market Size, By End-User, 2020-2026 (USD Million)

7.5.6 Brazil

7.5.6.1 Market Size, By Condition, 2020-2026 (USD Million)

7.5.6.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.5.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.5.7 Mexico

7.5.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.5.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.5.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.5.8 Argentina

7.5.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.5.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.5.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.6 MEA

7.6.1 Market Size, By Country 2020-2026 (USD Million)

7.6.2 Market Size, By Condition, 2020-2026 (USD Million)

7.6.3 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.6.4 Market Size, By End-User, 2020-2026 (USD Million)

7.6.6 Saudi Arabia

7.6.6.1 Market Size, By Condition, 2020-2026 (USD Million)

7.6.6.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.6.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.6.7 UAE

7.6.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.6.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.6.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.6.8 South Africa

7.6.7.1 Market Size, By Condition, 2020-2026 (USD Million)

7.6.7.2 Market Size, By Therapy Type, 2020-2026 (USD Million)

7.6.7.3 Market Size, By End-User, 2020-2026 (USD Million)

Chapter 8 Company Landscape

8.1 Competitive Analysis, 2020

8.2 Bristol-Myers Squibb Company

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Strategic Positioning

8.2.4 Info Graphic Analysis

8.3 Novartis AG

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Strategic Positioning

8.3.4 Info Graphic Analysis

8.4 Gilead Sciences

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Strategic Positioning

8.4.4 Info Graphic Analysis

8.5 bluebird bio, Inc.

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Strategic Positioning

8.5.4 Info Graphic Analysis

8.6 Amgen

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Strategic Positioning

8.6.4 Info Graphic Analysis

8.7 AstraZeneca

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Strategic Positioning

8.7.4 Info Graphic Analysis

8.8 F. Hoffmann-La Roche AG

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.9 Merck KGaA

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.10 Pfizer Inc.

8.10.1 Company Overview

8.10.2 Financial Analysis

8.10.3 Strategic Positioning

8.10.4 Info Graphic Analysis

8.11 Other Companies

8.11.1 Company Overview

8.11.2 Financial Analysis

8.11.3 Strategic Positioning

8.11.4 Info Graphic Analysis

The Global Hematological Malignancies Biotherapeutics Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Hematological Malignancies Biotherapeutics Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global hematological malignancies biotherapeutics market?

The global hematological malignancies biotherapeutics market size is projected to grow at a CAGR value of 10.8% from 2022 and 2027.

Who are the major vendors in the hematological malignancies biotherapeutics market?

Key and innovative vendors in the hematological malignancies biotherapeutics market include Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, bluebird bio, Inc., Amgen, AstraZeneca, F. Hoffmann-La Roche AG, Merck KGaA, Pfizer Inc., and Eli Lilly and Company, among others.

Which region has the highest market share in the hematological malignancies biotherapeutics market?

The North American region is estimated to hold the largest share of the hematological malignancies biotherapeutics market.

What is the Covid-19 impact on future hematological malignancies biotherapeutics manufacturers?

What are the major drivers in the hematological malignancies biotherapeutics market?